New Guidance in AT10 Clive Kearon, MD, PhD,
|
|
|
- Frank Osborne
- 5 years ago
- Views:
Transcription
1 New Guidance in AT10 Clive Kearon, MD, PhD, Professor, Department of Medicine, McMaster University; Program Director, McMaster Clinical Investigator Program, McMaster University Head, Clinical Thromboembolism Service, Juravinkl Hospital; Hamilton, Ontario Objectives: Define the role of aspirin as a means of secondary prevention of venous thromboembolism. Describe a decision-making process to determine whether to offer anticoagulant therapy to patients with isolated sub-segmental pulmonary embolism. Indicate the pharmacologic management options for patients who sustain a new event of venous thromboembolism while receiving therapeutic anticoagulation.
2 New Guidance in AT10 (Update ACCP/CHEST VTE Treatment) Thrombosis Guidelines April 2016 Murray, Utah Clive Kearon, McMaster University, Canada
3 Relevant Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Canadian Institutes Health Research D-dimer Optimal Duration Study (DODS) No relevant Boehringer Ingelheim Steering Committees & Bayer Inc. No relevant No relevant No relevant No relevant
4 ACPE Learning Objectives At the conclusion of this activity, participants should be able to successfully: Outline the role of aspirin as a means of secondary prevention of venous thromboembolism. Describe a decision-making process to determine whether to offer anticoagulant therapy to patients with isolated subsegmental pulmonary embolism. Indicate the pharmacologic management options for patients who sustain a new event of venous thromboembolism while receiving therapeutic anticoagulation.
5 Overview Topics updated Methods & Grading Recommendations (for selected topics)
6 Update Topics: Which & Why
7 Update Topics: Which & Why Old (in AT9) New evidence Controversial New New evidence Controversial Demand
8 Update Topics: Which & Why Old (in AT9) New evidence Controversial 12 topics 26 statements 49 recommends New New evidence Controversial Demand 3 topics 4 statements 5 recommends
9 Topics Choice of anticoagulant Duration of anticoagulant Aspirin for extended treatment Isolated distal DVT & anticoagulation Catheter Directed Thrombolysis for DVT IVC filters additional to anticoagulation Stockings to prevent PTS Subsegmental PE & anticoagulation Out of hospital PE treatment PE: Lytics, Route & Catheter-based (3) Thromboendarterectomy for CTEPH Upper DVT lytic therapy Recurrent VTE treatment
10 Topics Choice of anticoagulant Duration of anticoagulant Aspirin for extended treatment Isolated distal DVT & anticoagulation Catheter Directed Thrombolysis for DVT IVC filters additional to anticoagulation Stockings to prevent PTS Subsegmental PE & anticoagulation Out of hospital PE treatment PE: Lytics, Route & Catheter-based (3) Thromboendarterectomy for CTEPH Upper DVT lytic therapy Recurrent VTE treatment new new new
11 Topics Choice of anticoagulant Duration of anticoagulant Aspirin for extended treatment Isolated distal DVT & anticoagulation Catheter Directed Thrombolysis for DVT IVC filters additional to anticoagulation Stockings to prevent PTS Subsegmental PE & anticoagulation Out of hospital PE treatment PE: Lytics, Route & Catheter-based (3) Thromboendarterectomy for CTEPH Upper DVT lytic therapy Recurrent VTE treatment ACPE Learning Objectives new new new
12 Topics Choice of anticoagulant Duration of anticoagulant Aspirin for extended treatment Isolated distal DVT & anticoagulation Catheter directed thrombolysis for DVT IVC filters additional to anticoagulation Stockings to prevent PTS Subsegmental PE & anticoagulation Out of hospital PE treatment PE: Lytics, Route & Catheter-based (3) Thromboendarterectomy for CTEPH Upper DVT lytic therapy Recurrent VTE treatment Covered by others
13 Topics Choice of anticoagulant Duration of anticoagulant Aspirin for extended treatment Isolated distal DVT & anticoagulation Catheter directed thrombolysis for DVT IVC filters additional to anticoagulation Stockings to prevent PTS Subsegmental PE & anticoagulation Out of hospital PE treatment PE: Lytics, Route & Catheter-based (3) Thromboendarterectomy for CTEPH Upper DVT lytic therapy Recurrent VTE treatment Less interesting
14 6 Topics I will review Choice of anticoagulant Duration of anticoagulant Aspirin for extended treatment Isolated distal DVT & anticoagulation Catheter directed thrombolysis for DVT IVC filters additional to anticoagulation Stockings to prevent PTS Subsegmental PE & anticoagulation Out of hospital PE treatment PE: Lytics, Route & Catheter-based (3) Thromboendarterectomy for CTEPH Upper DVT lytic therapy Recurrent VTE treatment
15 Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report Clive Kearon; Elie Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher King; Timothy Morris; Namita Sood; Scott Stevens; Janine Vintch; Philip Wells; Scott Woller; Lisa Moores. CHEST 2016; 149:
16 Methods Systematic Review / Meta-Analysis Predefined outcomes (VTE, Bleeding, Mortality) Balance of benefits, harms/burden, costs Quality of evidence Recommendations
17 Grading of Recommendations
18 Grading of Recommendations Strength (For or Against) Grade 1: STRONG (stated as: We recommend ) clear benefit applies to most just do it Grade 2: WEAK (stated as: We suggest ) not large benefit or uncertain benefit Decision strongly influenced by: clinical differences patient preference
19 Grading of Recommendations Strength (For or Against) Grade 1: STRONG (stated as: We recommend ) clear benefit applies to most just do it Grade 2: WEAK (stated as: We suggest ) not large benefit or uncertain benefit Decision strongly influenced by: clinical differences patient preference Quality of Evidence A Randomized Trials Precise (narrow CIs) and Bias very unlikely and Consistent B Randomized Trials Less precise (wider CIs) or Bias likely but not major or Inconsistent C Randomized Trials Major limitations Observational Studies (only) not very strong or exceptional
20 Aspirin for extended treatment VTE?
21 ASA vs. Placebo for Extended Treatment Unprovoked VTE Studies: 2 Participants: 1,224 Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 VTE Mj Bleeding Mortality Simes Circ 2014
22 ASA vs. Placebo for Extended Treatment Unprovoked VTE Studies: 2 Participants: 1,224 Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 VTE Mj Bleeding Mortality Simes Circ 2014
23 ASA vs. Placebo for Extended Treatment Unprovoked VTE Studies: 2 Participants: 1,224 Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 VTE Mj Bleeding Mortality Simes Circ 2014
24 ASA vs. Placebo for Extended Treatment Unprovoked VTE Studies: 2 Participants: 1,224 Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 VTE Mj Bleeding Mortality Simes Circ 2014
25 Limitations Anticoagulants reduce VTE >80% DOACS suggested if unprovoked & low risk bleeding Bleeding may be similar with ASA & DOACs Both trials stopped early, and imprecision
26 Limitations Anticoagulants reduce VTE >80% DOACS suggested if unprovoked & low risk bleeding Bleeding may be similar with ASA & DOACs Both trials stopped early, and imprecision Unprovoked proximal DVT or PE & stop anticoags & no contraindication Aspirin over No aspirin Grade 2B
27 Isolated Distal DVT (guidelines discourage routine calf vein examination)
28 Isolated Distal DVT (guidelines discourage routine calf vein examination)
29 Isolated Distal DVT (guidelines discourage routine calf vein examination) Symptoms Not Severe AND No RF for Extension* Surveillance US over anticoagulation (eg, repeat at 1 & 2 wks) Grade 2C Severe Symptoms OR Risk Factors for Extension* Anticoagulation over surveillance US Grade 2C (*Suggested: positive D-dimer; extensive thrombosis; close to proximal; no reversible RF; cancer; previous VTE; inpatients)
30 IVC Filters for DVT or PE
31 IVC Filters for DVT or PE (AT9) Anticoagulated No Filter* Grade 1B Not Anticoagulated Filter Grade 1B (* may not apply to PE with hypotension) Usual anticoagulation if becomes feasible # Grade 2B ( # permanent filter not a reason for indefinite anticoagulation) Kearon et al CHEST 2012
32 IVCF vs. No IVCF if anticoagulated PE + DVT + 1 severity factor (RVD in 2/3) Studies: 1 Participants: 399 F-U & Temp IVCF: 3 mo PE-sympt* Mj Bleeding Mortality Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 * Fatal PE: 6/6 vs 2/3 Mismetti, PREPIC 2, JAMA 2015
33 IVCF vs. No IVCF if anticoagulated PE + DVT + 1 severity factor (RVD in 2/3) Studies: 1 Participants: 399 F-U & Temp IVCF: 3 mo PE-sympt* Mj Bleeding Mortality Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 * Fatal PE: 6/6 vs 2/3 Mismetti, PREPIC 2, JAMA 2015
34 IVCF vs. No IVCF if anticoagulated PE + DVT + 1 severity factor (RVD in 2/3) Studies: 1 Participants: 399 F-U & Temp IVCF: 3 mo PE-sympt* Mj Bleeding Mortality Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 * Fatal PE: 6/6 vs 2/3 Mismetti, PREPIC 2, JAMA 2015
35 IVCF vs. No IVCF if anticoagulated PE + DVT + 1 severity factor (RVD in 2/3) Studies: 1 Participants: 399 F-U & Temp IVCF: 3 mo PE-sympt* Mj Bleeding Mortality Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 * Fatal PE: 6/6 vs 2/3 Mismetti, PREPIC 2, JAMA 2015
36 IVC Filters for DVT or PE Anticoagulated No Filter* Grade 1B Not Anticoagulated Filter Grade 1B (* may not apply to PE with hypotension)
37 Stockings to prevent PTS?
38 Stockings to prevent PTS? AT9 Acute DVT GCS* Grade 2B (*30-40 mmhg ankle, 2 yrs)
39 GCS vs. Placebo after DVT Studies: 1 Participants: 803 F-U: 2 years PTS VTE Pain & QoL Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 Kahn, SOX, Lancet 2014
40 GCS vs. Placebo after DVT Studies: 1 Participants: 803 F-U: 2 years PTS VTE Pain & QoL Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 Kahn, SOX, Lancet 2014
41 GCS vs. Placebo after DVT Studies: 1 Participants: 803 F-U: 2 years PTS VTE Pain & QoL Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 Kahn, SOX, Lancet 2014
42 GCS vs. Placebo after DVT Studies: 1 Participants: 803 F-U: 2 years PTS VTE Pain & QoL Qual Evid (GRADE) Hazard Ratio Difference Per 1,000 Kahn, SOX, Lancet 2014
43 Stockings to prevent PTS? Acute DVT No GCS Grade 2B
44 Subsegmental PE (SSPE)
45 Subsegmental PE (SSPE) (must exclude proximal DVT if not anticoagulating)
46 SSPE & Recurrence Risk Convincing for SSPE good quality CTPA surrounded by contrast multiple larger ( 1 image/projection) Symptomatic, high CPTP D-dimer elevated (marked, unexplained)
47 SSPE & Recurrence Risk Convincing for SSPE good quality CTPA surrounded by contrast multiple larger ( 1 image/projection) Symptomatic, high CPTP Higher risk for progression hospitalized/immobile active cancer no reversible RF D-dimer elevated (marked, unexplained)
48 SSPE & Recurrence Risk Convincing for SSPE good quality CTPA surrounded by contrast multiple larger ( 1 image/projection) Symptomatic, high CPTP Higher risk for progression hospitalized/immobile active cancer no reversible RF D-dimer elevated (marked, unexplained) Others that favor no anticoagulation High bleeding risk; Good cardiopulmonary reserve Patient preference
49 SSPE & Recurrence Risk Convincing for SSPE good quality CTPA surrounded by contrast multiple larger ( 1 image/projection) Symptomatic, high CPTP Higher risk for progression hospitalized/immobile active cancer no reversible RF D-dimer elevated (marked, unexplained) Others that favor no anticoagulation High bleeding risk; Good cardiopulmonary reserve Patient preference
50 Subsegmental PE (SSPE) (must exclude proximal DVT if not anticoagulating) Lower Risk Recurrence Clinical surveillance over anticoagulation (may repeat proximal US at 1 ± 2 wks) Grade 2C Higher Risk Recurrence Anticoagulation over clinical surveillance Grade 2C
51 Recurrent VTE on Anticoagulants
52 Recurrent VTE on Anticoagulants Management will depend on circumstances
53 Recurrent VTE on Anticoagulants Management will depend on circumstances Treatment-related questions: true recurrence? started treatment recently? adherent? subtherapeutic INR? drug-induced lowering of DOAC? LMWH therapy? stepped down dose?
54 Recurrent VTE on Anticoagulants Management will depend on circumstances Patient-related questions: known cancer? cancer needs to be excluded? antiphospholipid antibody? lupus anticoagulant increasing INR? prothrombotic therapy (avoidable)?
55 Choice of anticoagulant No Cancer DOAC over VKA VKA over LMWH Grade 2B Grade 2C Cancer LMWH over DOAC or VKA Grade 2B
56 Recurrent VTE on Anticoagulants On DOAC or VKA (and no correctable cause) Switch to LMWH ( 1 mo) Grade 2C Already on LMWH (and no correctable cause) Increase dose ~25% ( 1 mo) Grade 2C
57 Take Home Messages Unprovoked VTE & Aspirin YES: if stopping anticoagulants & no contra Isolated distal DVT or SubSeg PE YES: some; NO: others (look selectively for DDVT; r/o proximal DVT; US surveillance) Temporary IVCF & anticoagulated PE: NO GCS to prevent PTS: NO Recurrent VTE on anticoagulants Correct cause, LMWH, higher dose LMWH
Accepted Manuscript. Antithrombotic Therapy for VTE Disease: CHEST Guideline
Accepted Manuscript Antithrombotic Therapy for VTE Disease: CHEST Guideline Clive Kearon, MD, PhD, Elie A. Akl, MD, MPH, PhD, Joseph Ornelas, PhD, Allen Blaivas, DO, FCCP, David Jimenez, MD, PhD, FCCP,
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
Simplified approach to investigation of suspected VTE
Simplified approach to investigation of suspected VTE Diagnosis of DVT and PE THSNA 2016, Chicago 15 April 2016 Clive Kearon, McMaster University, Canada Relevant Disclosures Research Support/P.I. Employee
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
Anticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra
Anticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra (whew!) Scott C. Woller, MD Co Director, Thrombosis Program Intermountain Medical Center Professor of Medicine University of Utah School
Diagnosis and Treatment of Pulmonary Embolism: High-Tech versus Low- Tech, which way to go?
Diagnosis and Treatment of Pulmonary Embolism: High-Tech versus Low- Tech, which way to go? Philip S. Wells MD, FRCPC, MSc Professor Chair and Chief, Department of Medicine, University of Ottawa DISCLOSURE
Clinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
DEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON How to Prevent and Manage the Post-Thrombotic Syndrome? Jean-Philippe Galanaud Clinical Thromboembolism & Division of GIM Sunnybrook,
Venous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
Thromboembolism and cancer: New practices. Marc Carrier
Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
Mechanical treatment for acute DVT. Laurent Casbas, MD Toulouse, France
Laurent Casbas, MD Toulouse, France Disclosure of Interest Speaker name: Laurent Casbas I have the following potential conflicts of interest to report: Consulting Medtronic General Electric Acute Venous
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
Updates in Management of Pulmonary Embolism (PE) David Ming, MD Duke Hospital Medicine July 24, 2017 Hilton Head, SC
Updates in Management of Pulmonary Embolism (PE) David Ming, MD Duke Hospital Medicine July 24, 2017 Hilton Head, SC Objectives Highlight clinical features and presentation of acute PE Analyze strategies
Controversies in Venous Thromboembolism
Controversies in Venous Thromboembolism Menaka Pai, BSc MSc MD FRCPC Assistant Professor, Department of Medicine, McMaster University Associate Member, Department of Pathology and Molecular Medicine, McMaster
The current ACCP guidelines fail clinicians and patients - Against
The current ACCP guidelines fail clinicians and patients - Against Henri Bounameaux, MD Professor of Medicine Dean, Faculty of Medicine, University of Geneva Director, Division of Angiology and Hemostasis
Understanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
PULMONARY EMBOLISM/VTE CARE PROCESS MODEL
PULMONARY EMBOLISM/VTE CARE PROCESS MODEL IMCP FALL CONFERENCE 2017 Scott Stevens, MD Co-Director, Thrombosis Clinic & Thrombosis Research Group Intermountain Medical Center Professor of Clinical Medicine
Mabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144 Appendix A: Summary of new evidence from Summary of evidence from previous year Diagnosis Diagnostic
Acute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
Inferior Vena Cava Filters
Inferior Vena Cava Filters and the American Society of Hematology Choosing Wisely Campaign Kevin P. Hubbard, DO, HMDC MACOI Chief - Division of Specialty Medicine Professor and Chair - Section of Internal
Pulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy
Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE
Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
Updates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
Blood Day for Primary Care
Blood Day for Primary Care including the Anticoagulation, use of novel oral anticoagulants in DVT/PE & atrial fibrillation Marc Carrier MD MSc. FRCPC Department of Internal Medicine, Division of Hematology,
Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach
Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Prof. I. Baumgartner Head Clinical and Interventional Angiology About the ACCP guidelines Widely
Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis
Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis Tim Sebastian, M.D. University Hospital Zurich Clinic for Angiology Disclosure Speaker name: Tim Sebastian I
Diagnosis and management of pulmonary embolism
Follow the link from the online version of this article to obtain certified continuing medical education credits bmj.com Respiratory Medicine updates from BMJ Group are at bmj.com/specialties/respiratory-medicine
Risk-Based Evaluation and Management of VTE
12:50-1:50pm Risk-Based Evaluation and Management of VTE SPEAKER Gregory Piazza, MD, MS BRIGHAM AND WOMEN S HOSPITAL Risk-Based Evaluation and Management of VTE Gregory Piazza, MD, MS Assistant Professor
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
Updates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)
Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Clinical Learning Day 2017 Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain
Duration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
Top 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE
Top 5 (or so) Hematology Consults Tom FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none 1 What I am Talking About
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
The Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
DOACs and CAT. 05 May 2017 NTW St Thomas Hospital
DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen
Aspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
VTE General Background
VTE General Background VTE incidence is about 1:1000 persons annually >250,000 admissions for VTE annually >100,000 people die of PE annually >90% of PE s arise from lower limb DVT 50% of DVT at diagnosis
Duration of anticoagulation
Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,
Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD
Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD
Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
Updates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE Financial Disclosures-NONE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA,
The latest on the diagnosis and treatment of venous thromboembolism
The latest on the diagnosis and treatment of venous thromboembolism Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer
Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens
Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens Faculty disclosure Marie Antoinette Sevestre I disclose the following financial relationships: Paid
Anticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
Prevention of VTE Sequelae: Post-thrombotic Syndrome and Chronic Thromboembolic Pulmonary Hypertension
Prevention of VTE Sequelae: Post-thrombotic Syndrome and Chronic Thromboembolic Pulmonary Hypertension Susan R. Kahn MD MSc Professor of Medicine, McGill University Director, Jewish General Hospital Centre
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski Department of Surgery Grand Rounds March 24, 2008 History of Vena Cava Filters Virchow-1846-Proposes PE originate from veins
Rapid Fire-Top Articles You Need to Know
Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
Epidemiology of Pulmonary Embolism (PE)
Why Treat Submassive PE Abstract: Massive Pulmonary Embolism (PE) requires immediate lifesaving intervention for the patient. For the submassive PE patient, characterized by presence of right ventricular
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
IDEAL MANAGEMENT OF PULMONARY EMBOLISM DISCLOSURES
IDEAL MANAGEMENT OF PULMONARY EMBOLISM Samuel Z. Goldhaber, MD Section Head, Vascular Medicine Director, Thrombosis Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine
Anticoagulation Forum: Management of Tiny Clots
Anticoagulation Forum: Management of Tiny Clots Casey O Connell, MD FACP Associate Professor Jane Anne Nohl Division of Hematology Keck School of Medicine USC DISCLOSURES None 4/11/2017 Objectives Define
The clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
DOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome
Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome Catherine K. Chang, MD FACS Vascular Surgery San Diego Southern California Permanente Medical Group Acute Deep Venous Thrombosis Incidence & Outcomes
How long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
Epidemiology. Update on Pulmonary Embolism. Keys to PE Management 5/5/2014. Diagnosis. Risk stratification. Treatment
Update on Pulmonary Embolism Steven M. Dean, DO, FACP, RPVI Program Director- Vascular Medicine Associate Professor of Internal Medicine Division of Cardiovascular Medicine The Ohio State University Keys
A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
This chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
Venous thrombosis in unusual sites
Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers
Status of anticoagulation therapy in 2016: Is there a need for venous revascularization?
Status of anticoagulation therapy in 2016: Is there a need for venous revascularization? Rupert M. Bauersachs Dept. of Vascular Medicine, Darmstadt Center of Thrombosis Hemostasis, Mainz Status of anticoagulation
Top Ten Reasons For Failure To Prevent Postoperative Thrombosis
Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical
Management of Pulmonary Embolism. Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School
Management of Pulmonary Embolism Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School I have no conflicts of interest to report. VTE Overview
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
Bayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
Acute and long-term treatment of VTE. Cecilia Becattini University of Perugia
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
Management of Cancer Associated Thrombosis (CAT) where data is lacking. Tim Nokes Haematologist, Derriford Hospital, Plymouth
Management of Cancer Associated Thrombosis (CAT) where data is lacking Tim Nokes Haematologist, Derriford Hospital, Plymouth Contents Overview of the statistics and aetiology for Cancer Associated Thrombosis
Venous Thromboembolism Management: Bridging the Gap Between Inpatient and Outpatient. Disclosure. Technician Objectives. Pharmacist Objectives
Venous Thromboembolism Management: Bridging the Gap Between Inpatient and Outpatient Alexander Kantorovich, Pharm.D., BCPS Clinical Assistant Professor Chicago State University College of Pharmacy Clinical
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial Wednesday, June 6, 2018, 2:00PM ET Guest Author: David R. Anderson, MD Presenter: Sara Vazquez, PharmD Moderators:
DEEP VENOUS THROMBOSIS A PRACTICAL APPROACH TO IMPROVING CLINICAL OUTCOMES
DEEP VENOUS THROMBOSIS A PRACTICAL APPROACH TO IMPROVING CLINICAL OUTCOMES Jose M. Borromeo M.D. Vascular Surgeon Iowa Heart Center Disclosures: AstraZeneca Pharmaceuticals Cook CVRx LeMaitre Vascular,
DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
Keynote lecture: Oral anticoagulation and DVT
Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT? Disclosure Speaker name:...sebastian Schellong... I have the following potential
New areas of development for the direct oral anticoagulants
New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory
The spectrum of clinical outcome of PE
Practical treatment approach for patients with PE Cecilia Becattini University of Perugia The spectrum of clinical presentation of PE PE-related shock Mild clinical symptoms The spectrum of clinical outcome
How to prevent thrombotic diseases? Sergio Fusco, MD
How to prevent thrombotic diseases? Sergio Fusco, MD Geriatric Division - Department of Internal Medicine Ospedale Dell'Angelo - Venice, Italy CONFLICT OF INTEREST DISCLOSURE I have no potential conflict
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
Pulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical
Pulmonary embolus - a practical approach to investigation and treatment Sam Janes Wellcome Senior Fellow and Respiratory Physician, University College London Background Diagnosis Treatment Common: 50 cases
DVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
Perioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
Objectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
Not all Leg DVT s are the Same: Which Patients Benefit from Interventional Therapy? Case 1:
12/16/2015 Not all Leg DVT s are the Same: Which Patients Benefit from Interventional Therapy? Constantino S.Peña, FSIR, FSCCT, FAHA Interventional Radiologist Medical Director, Vascular Imaging Miami
CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum
Online Data Supplement Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Stacey M. Kassutto, C. Jessica Dine, Maryl Kreider, Rupal
DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
Prophylaxie primaire sur le patient ambulatoire. Marc Carrier
Prophylaxie primaire sur le patient ambulatoire Marc Carrier Marc Carrier In compliance with COI policy, SSVQ requires the following disclosures to the session audience: Research Support/P.I. Employee